These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30248593)

  • 41. Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies.
    Khatri BO; Tarima SS; Essig B; Sesing J; Olapo T
    Mult Scler Relat Disord; 2017 Nov; 18():60-64. PubMed ID: 29141823
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.
    Havla J; Warnke C; Derfuss T; Kappos L; Hartung HP; Hohlfeld R
    Dtsch Arztebl Int; 2016 Dec; 113(51-52):879-886. PubMed ID: 28130920
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disease-modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta-analysis.
    Valizadeh A; Fattahi MR; Sadeghi M; Saghab Torbati M; Sahraian MA; Azimi AR
    CNS Neurosci Ther; 2022 May; 28(5):648-657. PubMed ID: 35218155
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Rae-Grant A; Day GS; Marrie RA; Rabinstein A; Cree BAC; Gronseth GS; Haboubi M; Halper J; Hosey JP; Jones DE; Lisak R; Pelletier D; Potrebic S; Sitcov C; Sommers R; Stachowiak J; Getchius TSD; Merillat SA; Pringsheim T
    Neurology; 2018 Apr; 90(17):777-788. PubMed ID: 29686116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
    Fernández Ó
    Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials.
    Zhao Z; Ma CL; Gu ZC; Dong Y; Lv Y; Zhong MK
    Front Immunol; 2021; 12():611711. PubMed ID: 33763062
    [No Abstract]   [Full Text] [Related]  

  • 47. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.
    Mardan J; Hussain MA; Allan M; Grech LB
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1273-1295. PubMed ID: 34464209
    [No Abstract]   [Full Text] [Related]  

  • 48. Psychological therapies for pathological and problem gambling.
    Cowlishaw S; Merkouris S; Dowling N; Anderson C; Jackson A; Thomas S
    Cochrane Database Syst Rev; 2012 Nov; 11():CD008937. PubMed ID: 23152266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Psychological therapies for the treatment of post-traumatic stress disorder in children and adolescents (Review).
    Gillies D; Taylor F; Gray C; O'Brien L; D'Abrew N
    Evid Based Child Health; 2013 May; 8(3):1004-116. PubMed ID: 23877914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY; Constantinescu CS
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Post marketing new adverse effects of oral therapies in multiple sclerosis: A systematic review.
    Sahraian MA; Salehi AM; Jenabi E; Esfahani ME; Ataei S
    Mult Scler Relat Disord; 2022 Dec; 68():104157. PubMed ID: 36122472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
    Menzin J; Caon C; Nichols C; White LA; Friedman M; Pill MW
    J Manag Care Pharm; 2013; 19(1 Suppl A):S24-40. PubMed ID: 23383731
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
    Ng HS; Kingwell E; Zhu F; Zhang T; Marrie RA; Carruthers R; Tremlett H
    Mult Scler; 2021 Feb; 27(2):239-249. PubMed ID: 32141376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis.
    Hellwig K; Verdun di Cantogno E; Sabidó M
    Ther Adv Neurol Disord; 2021; 14():17562864211051012. PubMed ID: 34876925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies.
    Porwal MH; Salter A; Patel D; Obeidat AZ
    J Cent Nerv Syst Dis; 2022; 14():11795735221109674. PubMed ID: 35769950
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.